ANNEX 3

Regional profiles
FOR
6 WHO REGIONS
WHO MEMBER STATES 47

Estimates of TB burdena 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>450 (350–560)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>310 (270–350)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>3 200 (2 800–3 600)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>2 700 (2 400–3 000)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>870 (790–950)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>48 (43–54)</td>
</tr>
</tbody>
</table>

Estimates of MDR-TB burdenb 2014

<table>
<thead>
<tr>
<th>NEW RETREATMENT</th>
<th>%</th>
<th>NEW RETREATMENT</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>2.1 (0.5–3.7)</td>
<td>11 (6.7–16)</td>
<td></td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>22 000 (5 200–38 000)</td>
<td>11 000 (6 200–15 000)</td>
<td></td>
</tr>
</tbody>
</table>

TB case notifications 2014

<table>
<thead>
<tr>
<th>NEW RELAPSE</th>
<th>Pulmonary, bacteriologically confirmed</th>
<th>Pulmonary, clinically diagnosed</th>
<th>Extrapulmonary</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>635 560</td>
<td>39 782</td>
<td>212 057</td>
</tr>
</tbody>
</table>

Total new and relapse | 1 300 852 |

Prevalent cases notified | 1 342 400 |

Among 1 054 331 reported new and relapse cases disaggregated by age, 90 523 (8.6%) cases were aged < 15 years

Among 1 056 629 reported new and relapse cases disaggregated by sex, male:female ratio = 1.4

Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th>NEW RETREATMENT TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment</td>
</tr>
</tbody>
</table>

TB/HIV 2014

| TB patients with known HIV status | 1 064 385 | 79 |
| HIV-positive TB patients | 415 657 | 39 |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) | 360 015 | 89 |
| HIV-positive TB patients on antiretroviral therapy (ART) | 377 773 | 77 |
| HIV-positive people screened for TB | 5 166 166 |
| HIV-positive people provided with IPT | 875 886 |

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>%</th>
<th>NEW RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>79</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>70</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>70</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>53</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>20</td>
</tr>
</tbody>
</table>

Laboratories 2014

<table>
<thead>
<tr>
<th>NUMBER OF MEMBER STATES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sputum smear positive (per 100 000 population) ≥ 1</td>
</tr>
<tr>
<td>Culture positive (per 5 million population) ≥ 1</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population) ≥ 1</td>
</tr>
</tbody>
</table>

Financing TB control (low- and middle-income countries)c,d 2015

| National TB programme budget (US$ millions) | 1 080 |
| % Funded domestically | 34 |
| % Funded internationally | 29 |
| % Unfunded | 37 |

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Ranges represent uncertainty intervals.

Includes cases with unknown previous TB treatment history.

Some countries reported on new cases only.

Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

Calculations exclude countries with missing numerators or denominators.

Data are not collected from all Member States.

Financing indicators exclude funding for general healthcare services provided outside NTPs.

GLOBAL TUBERCULOSIS REPORT 2015 149
WHO/PAHO Region of the Americas  
Population 2014 982 million

WHO MEMBER STATES 35 | OTHER COUNTRIES AND TERRITORIES 11

**Estimates of TB burden** 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>17 (16–18)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>6 (5–7)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>350 (270–440)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>280 (270–290)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>36 (34–38)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>77 (75–81)</td>
</tr>
</tbody>
</table>

**Estimates of MDR-TB burden** 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>2.4 (1.3–3.5)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>4 000 (2,200–5,900)</td>
</tr>
</tbody>
</table>

**TB case notifications 2014**

<table>
<thead>
<tr>
<th>NEW</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>127,864</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>40,746</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>32,501</td>
</tr>
<tr>
<td>Total new and relapse</td>
<td>215,243</td>
</tr>
<tr>
<td>Previously treated, excluding relapses</td>
<td>13,233</td>
</tr>
<tr>
<td>Total cases notified</td>
<td>228,476</td>
</tr>
</tbody>
</table>

Among 208,839 reported new and relapse cases disaggregated by age, 10,489 (5.0%) cases were aged < 15 years
Among 210,774 reported new and relapse cases disaggregated by sex, male:female ratio = 1.7

**Reported cases of RR-/MDR-TB 2014**

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>30,531 (24%)</td>
<td></td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>7,745</td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment</td>
<td>3,568</td>
<td></td>
</tr>
</tbody>
</table>

**TB/HIV 2014**

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
</tr>
</tbody>
</table>

**Treatment success rate and cohort size**

<table>
<thead>
<tr>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>75 (200,726)</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>48 (14,753)</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>53 (19,816)</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>57 (2,866)</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>30 (67)</td>
</tr>
</tbody>
</table>

**Laboratories 2014**

<table>
<thead>
<tr>
<th>NUMBER OF MEMBER STATES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100 000 population) ≥ 1</td>
</tr>
<tr>
<td>Culture (per 5 million population) ≥ 1</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population) ≥ 1</td>
</tr>
</tbody>
</table>

**Financing TB control (low- and middle-income countries)**

| National TB programme budget (US$ millions) | 285 |
| % Funded domestically | 71 |
| % Funded internationally | 7.3 |
| % Unfunded | 22 |

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

- Ranges represent uncertainty intervals.
- Includes cases with unknown previous TB treatment history.
- Some countries reported on new cases only.
- Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.
- Calculations exclude countries with missing numerators or denominators.
- Data are not collected from all Member States.
- Funding indicators exclude funding for general healthcare services provided outside NTPs.

WHO/PAHO Region of the Americas  
Population 2014 982 million

WHO MEMBER STATES 35 | OTHER COUNTRIES AND TERRITORIES 11

**Estimates of TB burden** 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>17 (16–18)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>6 (5–7)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>350 (270–440)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>280 (270–290)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>36 (34–38)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>77 (75–81)</td>
</tr>
</tbody>
</table>

**Estimates of MDR-TB burden** 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>2.4 (1.3–3.5)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>4 000 (2,200–5,900)</td>
</tr>
</tbody>
</table>

**TB case notifications 2014**

<table>
<thead>
<tr>
<th>NEW</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>127,864</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>40,746</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>32,501</td>
</tr>
<tr>
<td>Total new and relapse</td>
<td>215,243</td>
</tr>
<tr>
<td>Previously treated, excluding relapses</td>
<td>13,233</td>
</tr>
<tr>
<td>Total cases notified</td>
<td>228,476</td>
</tr>
</tbody>
</table>

Among 208,839 reported new and relapse cases disaggregated by age, 10,489 (5.0%) cases were aged < 15 years
Among 210,774 reported new and relapse cases disaggregated by sex, male:female ratio = 1.7

**Reported cases of RR-/MDR-TB 2014**

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>30,531 (24%)</td>
<td></td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>7,745</td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment</td>
<td>3,568</td>
<td></td>
</tr>
</tbody>
</table>

**TB/HIV 2014**

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
</tr>
</tbody>
</table>

**Treatment success rate and cohort size**

<table>
<thead>
<tr>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>75 (200,726)</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>48 (14,753)</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>53 (19,816)</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>57 (2,866)</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>30 (67)</td>
</tr>
</tbody>
</table>

**Laboratories 2014**

<table>
<thead>
<tr>
<th>NUMBER OF MEMBER STATES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100 000 population) ≥ 1</td>
</tr>
<tr>
<td>Culture (per 5 million population) ≥ 1</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population) ≥ 1</td>
</tr>
</tbody>
</table>

**Financing TB control (low- and middle-income countries)**

| National TB programme budget (US$ millions) | 285 |
| % Funded domestically | 71 |
| % Funded internationally | 7.3 |
| % Unfunded | 22 |

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

- Ranges represent uncertainty intervals.
- Includes cases with unknown previous TB treatment history.
- Some countries reported on new cases only.
- Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.
- Calculations exclude countries with missing numerators or denominators.
- Data are not collected from all Member States.
- Funding indicators exclude funding for general healthcare services provided outside NTPs.
### WHO Member States 21 | Other Countries and Territories 1

#### Estimates of TB burden\(^a\) 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>88 (43–150)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>3 (3–4)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>1 000 (880–1 200)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>740 (610–890)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>12 (10–15)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>61 (51–75)</td>
</tr>
</tbody>
</table>

#### Estimates of MDR-TB burden\(^a\) 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>3.2 (2.3–4.1)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>11 000 (7 700–14 000)</td>
</tr>
</tbody>
</table>

#### TB case notifications 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>182 630</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>151 696</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>103 959</td>
</tr>
</tbody>
</table>

Total new and relapse: 431 393

Previously treated, excluding relapses: 12 284

Total cases notified: 463 677

Among 441 071 reported new and relapse cases disaggregated by age, 42 028 (9.5%) cases were aged < 15 years

Among 449 016 reported new and relapse cases disaggregated by sex, male:female ratio = 1.0

#### Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th>NUMBER</th>
<th>(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
<td>67 624</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
<td>1 629</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
<td>686</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
<td>943</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
<td>14 775</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
<td>478</td>
</tr>
</tbody>
</table>

#### Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>(%)</th>
<th>COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>91</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>76</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>60</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>65</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>33</td>
</tr>
</tbody>
</table>

#### Laboratories 2014

| NUMBER OF MEMBER STATES | |
|-------------------------||
| Smear (per 100 000 population) ≥ 1 | 3 out of 15 |
| Culture (per 5 million population) ≥ 1 | 9 out of 15 |
| Drug susceptibility testing (per 5 million population) ≥ 1 | 4 out of 15 |

#### Financing TB control (low- and middle-income countries)\(^{g}\) 2015

| National TB programme budget (US$ millions) | 183 |
| % Funded domestically | 46 |
| % Funded internationally | 43 |
| % Unfunded | 11 |

### Data for all years can be downloaded from [www.who.int/tb/data](http://www.who.int/tb/data)
**WHO Member States 53 | Other Countries and Territories 1**

### Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>33 (33–34)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>3 (3–4)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>440 (330–560)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>340 (320–350)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>20 (18–21)</td>
</tr>
</tbody>
</table>

Case detection, all forms (%): 79 (75–83)

### Estimates of MDR-TB burden* 2014

#### NEW RETREATMENT

| % of TB cases with MDR-TB | 15 (10–19) |
| MDR-TB cases among notified pulmonary TB cases | 28,000 (20,000–37,000) |

#### Piano

<table>
<thead>
<tr>
<th>Population 2014</th>
<th>907 million</th>
</tr>
</thead>
</table>

### TB case notifications 2014

#### NEW<sup>a</sup> RELAPSE

| Pulmonary, bacteriologically confirmed | 112,416 |
| Pulmonary, clinically diagnosed | 76,759 |
| Extrapulmonary | 39,175 |

### Total new and relapse

266,058

### Previously treated, excluding relapses

55,363

### Total cases notified

321,421

### Among 260,844 reported new and relapse<sup>b</sup> cases disaggregated by age, 9,898 (3.8%) cases were aged <15 years

### Among 261,563 reported new and relapse<sup>c</sup> cases disaggregated by sex, male:female ratio = 2.0

### Reported cases of RR-/MDR-TB 2014

### NEW RETREATMENT TOTAL<sup>d</sup>

| Laboratory-confirmed RR-/MDR-TB cases | 42,293 |
| Patients started on MDR-TB treatment<sup>e</sup> | 49,074 |

### TB/HIV 2014

#### NUMBER (%)<sup>e</sup>

| HIV-positive TB patients | 16,630 |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) | 5,452 |
| HIV-positive TB patients on antiretroviral therapy (ART) | 6,279 |
| HIV-positive people screened for TB | 37,266 |
| HIV-positive people provided with IPT | 21,014 |

### Treatment success rate and cohort size

#### Number of TB patients (thousands)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td>20</td>
<td>25</td>
</tr>
</tbody>
</table>

### Laboratories 2014

#### NUMBER OF MEMBER STATES<sup>d</sup>

| Smear (per 100,000 population) ≥ 1 | 10 out of 53 |
| Culture (per 5 million population) ≥ 1 | 44 out of 53 |

### Drug susceptibility testing (per 5 million population) ≥ 1

39 out of 53

### Financing TB control (low- and middle-income countries)<sup>f,g</sup> 2015

| National TB programme budget (US$ millions) | 2,513 |
| % Funded domestically | 93 |
| % Funded internationally | 4.1 |
| % Unfunded | 2.5 |

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

<sup>a</sup> Ranges represent uncertainty intervals.
<sup>b</sup> Includes cases with unknown previous TB treatment history.
<sup>c</sup> Some countries reported on new cases only.
<sup>d</sup> Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.
<sup>e</sup> Calculations exclude countries with missing numerators or denominators.
<sup>f</sup> Data are not collected from all Member States.
<sup>g</sup> Financing indicators exclude funding for general healthcare services provided outside NTPs.
### WHO Member States 11

#### Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>460 (350–570)</td>
<td>2.4 (19–30)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>62 (51–74)</td>
<td>3.3 (2.7–3.9)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>5 400 (4 400–6 500)</td>
<td>286 (233–343)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>4 000 (3 700–4 400)</td>
<td>211 (192–232)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>210 (180–240)</td>
<td>11 (9.4–12)</td>
</tr>
</tbody>
</table>

#### Case detection, all forms (%) 2014

|                  | 62 (56–68) |

#### Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>2.2 (1.9–2.6)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>40 000 (35 000–47 000)</td>
</tr>
</tbody>
</table>

#### TB case notifications 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>1 188 654</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>632 418</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>389 819</td>
</tr>
<tr>
<td>Total new and relapse</td>
<td>2 482 076</td>
</tr>
<tr>
<td>Previously treated, excluding relapses</td>
<td>98 531</td>
</tr>
<tr>
<td>Total cases notified</td>
<td>2 580 605</td>
</tr>
</tbody>
</table>

Among 2 416 375 reported new and relapse cases disaggregated by age, 168 310 (7.0%) cases were aged <15 years

Among 2 435 769 reported new and relapse cases disaggregated by sex, male:female ratio = 1.8

#### Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th></th>
<th>NEW RETREATMENT TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>45 056 (3.8%)</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>33 264</td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment*</td>
<td>28 536</td>
</tr>
</tbody>
</table>

#### TB/HIV 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER (%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
<td>1 171 258</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
<td>60 235</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
<td>51 141</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
<td>51 231</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
<td>1 183 007</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
<td>3 049</td>
</tr>
</tbody>
</table>

#### Treatment success rate and cohort size

<table>
<thead>
<tr>
<th></th>
<th>(% COHORT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
<td>88 (2 100 508)</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
<td>67 (196 439)</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
<td>74 (54 235)</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
<td>49 (11 566)</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
<td>37 (1 018)</td>
</tr>
</tbody>
</table>

#### Laboratories 2014

<table>
<thead>
<tr>
<th></th>
<th>NUMBER OF MEMBER STATES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100 000 population) ≥ 1</td>
<td>9 out of 11</td>
</tr>
<tr>
<td>Culture (per 5 million population) ≥ 1</td>
<td>3 out of 11</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population) ≥ 1</td>
<td>2 out of 11</td>
</tr>
</tbody>
</table>

#### Financing TB control (low- and middle-income countries)* 2015

<table>
<thead>
<tr>
<th></th>
<th>National TB programme budget (US$ millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Funded domestically</td>
<td>33</td>
</tr>
<tr>
<td>% Funded internationally</td>
<td>45</td>
</tr>
<tr>
<td>% Unfunded</td>
<td>22</td>
</tr>
</tbody>
</table>

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

* Ranges represent uncertainty intervals.

** Includes cases with unknown previous TB treatment history.

† Some countries reported new cases only.

‡ Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

§ Calculations exclude countries with missing numerators or denominators.

¶ Data are not collected from all Member States.

‖ Calculations exclude funding for general healthcare services provided outside NTPs.
WHO MEMBER STATES 27 | OTHER COUNTRIES AND TERRITORIES 9

Estimates of TB burden* 2014

<table>
<thead>
<tr>
<th>NUMBER (thousands)</th>
<th>RATE (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>88 (81–95)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>5 (4–6)</td>
</tr>
<tr>
<td>Prevalence (includes HIV+TB)</td>
<td>2,100 (1,900–2,400)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>1,600 (1,300–1,600)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>31 (28–35)</td>
</tr>
<tr>
<td>Case detection, all forms (%)</td>
<td>85 (81–90)</td>
</tr>
</tbody>
</table>

Estimates of MDR-TB burden* 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of TB cases with MDR-TB</td>
<td>4.4 (2.5–6.3)</td>
</tr>
<tr>
<td>MDR-TB cases among notified pulmonary TB cases</td>
<td>52,000 (30,000–75,000)</td>
</tr>
</tbody>
</table>

TB case notifications 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RELAPSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary, bacteriologically confirmed</td>
<td>449,845</td>
</tr>
<tr>
<td>Pulmonary, clinically diagnosed</td>
<td>734,179</td>
</tr>
<tr>
<td>Extrapulmonary</td>
<td>103,085</td>
</tr>
</tbody>
</table>

Total new and relapse | 1,335,816 |

Previously treated, excluding relapses | 39,756 |

Total cases notified | 1,375,572 |

Among 1,100,525 reported new and relapse cases disaggregated by age, 37,273 (3.4%) cases were aged < 15 years

Among 1,112,985 reported new and relapse cases disaggregated by sex, male:female ratio = 2.1

Reported cases of RR-/MDR-TB 2014

<table>
<thead>
<tr>
<th>NEW</th>
<th>RETREATMENT</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases tested for RR-/MDR-TB</td>
<td>92,801 (21%)</td>
<td>54,560 (62%)</td>
</tr>
<tr>
<td>Laboratory-confirmed RR-/MDR-TB cases</td>
<td>13,437</td>
<td></td>
</tr>
<tr>
<td>Patients started on MDR-TB treatment</td>
<td>8,850</td>
<td></td>
</tr>
</tbody>
</table>

TB/HIV 2014

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB patients with known HIV status</td>
</tr>
<tr>
<td>HIV-positive TB patients</td>
</tr>
<tr>
<td>HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)</td>
</tr>
<tr>
<td>HIV-positive TB patients on antiretroviral therapy (ART)</td>
</tr>
<tr>
<td>HIV-positive people screened for TB</td>
</tr>
<tr>
<td>HIV-positive people provided with IPT</td>
</tr>
</tbody>
</table>

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>(%) COHORT</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2013</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2013</td>
</tr>
<tr>
<td>HIV-positive TB cases, all types, registered in 2013</td>
</tr>
<tr>
<td>RR-/MDR-TB cases started on second-line treatment in 2012</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2012</td>
</tr>
</tbody>
</table>

Laboratories 2014

<table>
<thead>
<tr>
<th>NUMBER OF MEMBER STATES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smear (per 100 000 population) ≥ 1</td>
</tr>
<tr>
<td>Culture (per 5 million population) ≥ 1</td>
</tr>
<tr>
<td>Drug susceptibility testing (per 5 million population) ≥ 1</td>
</tr>
</tbody>
</table>

Financing TB control (low- and middle-income countries) 1-5 2015

National TB programme budget (US$ millions) | 603 |
| Funded domestically | 63 |
| Funded internationally | 16 |
| Unfunded | 22 |

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

* Ranges represent uncertainty intervals.

† Includes cases with known previous TB treatment history.

‡ Some countries reported on new cases only.

§ Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB.

¶ Calculations exclude countries with missing numerators or denominators.

∥ Data are not collected from all Member States.

© Financing indicators exclude funding for general healthcare services provided outside NTPs.